Background The coronavirus disease 2019 (COVID-19) caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to plague the world. While …

Objectives We performed a systematic review and network meta-analysis of randomized
controlled trials (RCTs) to provide updated information regarding the clinical efficacy of …

An updated version of this article was published on 1 March 2022. Background: Remdesivir
is being studied and used for treatment of coronavirus disease 2019 (COVID-19). Purpose …

Purpose This review was aimed to synthesise the best available evidence on the
effectiveness and safety of remdesivir in the treatment of moderate to severe COVID-19 …

Background Real-world data on safety and clinical outcomes of remdesivir in COVID-19
management is scant. We present findings of data analysis conducted for assessing the …

Objectives Evaluation of remdesivir, an RNA polymerase inhibitor, for effectiveness in adults
with COVID-19. Data sources Electronic search for eligible articles of PubMed, Cochrane …

Remdesivir (Veklury®), a nucleotide analogue prodrug with broad-spectrum antiviral activity,
is approved for the treatment of coronavirus disease 2019 (COVID-19), the illness caused by …

BACKGROUND Coronavirus disease 2019 (COVID-19) has left a significant impact on the
world's health, economic and political systems; as of November 20, 2020, more than 57 …

Background: Remdesivir is approved for the treatment of adults hospitalized with COVID-19.
Purpose: To update a living review of remdesivir for adults with COVID-19. Data Sources …

Background Remdesivir is an antiviral medicine approved for the treatment of mild‐to‐
moderate coronavirus disease 2019 (COVID‐19). This led to widespread implementation …